(Q36982570)

17 August 2017

1 reference

title

Prodrug strategies in anticancer chemotherapy (English)

1 reference

17 August 2017

1 reference

Felix Kratz

1

1 reference

17 August 2017

Ivonne A Müller

series ordinal

2

1 reference

17 August 2017

Claudia Ryppa

series ordinal

3

1 reference

17 August 2017

André Warnecke

series ordinal

4

1 reference

17 August 2017

1 January 2008

1 reference

17 August 2017

1 reference

17 August 2017

3

1 reference

17 August 2017

20-53

1 reference

17 August 2017

1

1 reference

Antibodies and peptides in cancer therapy

17 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

Monoclonal antibodies in the treatment of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

Antibody directed enzymes revive anti-cancer prodrugs concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

The biology of the Ets1 proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

Drug-polymer conjugates containing acid-cleavable bonds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

Microtubulin binding sites as target for developing anticancer agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

N-(2-Hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

Cell surface complex of cathepsin B/annexin II tetramer in malignant progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

Enzyme-catalyzed activation of anticancer prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Lessons learned from marketed and investigational prodrugs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

New approaches to antibody therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Monoclonal antibody-based therapy strategies: providing options for the cancer patient

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Antibody-cytotoxic agent conjugates for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Technology insight: cytotoxic drug immunoconjugates for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Monoclonal antibody drug immunoconjugates for targeted treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Recent advances in tumor-targeting anticancer drug conjugates.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Arming antibodies: prospects and challenges for immunoconjugates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Monoclonal antibody therapeutics and apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.200700159

1 reference

7 January 2021

Lecture for the Nobel Prize for physiology or medicine 1972: Structural studies of immunoglobulins. 1972.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Crystallographic structure of an intact IgG1 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Monoclonal antibody therapy of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Progress in immunoconjugate cancer therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Antibody targeted drugs as cancer therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Drug-conjugated monoclonal antibodies for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Transferrin: structure, function and potential therapeutic actions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Selectins--potential pharmacological targets?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Coming to grips with integrin binding to ligands

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Glucose transporters: expression, regulation and cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Novel peptide conjugates for tumor-specific chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

D-19575--a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Serum proteins as drug carriers of anticancer agents: a review

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.200700159

1 reference

7 January 2021

Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Folate receptors in malignant and benign tissues of human female genital tract.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Targeted drug delivery to chemoresistant cells: folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Synthesis and evaluation of pteroic acid-conjugated nitroheterocyclic phosphoramidates as folate receptor-targeted alkylating agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Synthesis and activity of a folate peptide camptothecin prodrug

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Integrins in drug targeting-RGD templates in toxins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Lectin-mediated drug targeting: selection of valency, sugar type (Gal/Lac), and spacer length for cluster glycosides as parameters to distinguish ligand binding to C-type asialoglycoprotein receptors and galectins.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Carbohydrate-Specific Receptors of the Liver

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The asialoglycoprotein receptor: relationships between structure, function, and expression

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The cluster glycoside effect

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Galactose-carrying polymers as extracellular matrices for liver tissue engineering

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Synthesis of a novel glycoconjugated chitosan and preparation of its derived nanoparticles for targeting HepG2 cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Differential chemoprotection against acetaminophen-induced hepatotoxicity by latentiated L-cysteines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Specific targeting of a lipophilic prodrug of iododeoxyuridine to parenchymal liver cells using lactosylated reconstituted high density lipoprotein particles

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Liver-targeted doxorubicin: effects on rat regenerating hepatocytes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Coupling of lactose molecules to the carrier protein hinders the spleen and bone marrow uptake of doxorubicin conjugated with human albumin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

On the Specificity of Antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Evidence for multispecificity of antibody molecules

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Transport of molecules, particles, and cells in solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Transforming the cell surface through proteolysis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Antibody-dependent difference in biodistribution of monoclonal antibodies in animal models and humans

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Developments with targeted enzymes in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Enzyme / Abzyme Prodrug Activation Systems: Potential Use in Clinical Oncology

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Antibody-directed enzyme prodrug therapy (ADEPT) for cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.200700159

1 reference

7 January 2021

A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Exploiting the enhanced permeability and retention effect for tumor targeting

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Drug delivery and transport to solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Macromolecular contrast agents for optical imaging of tumors: comparison of indotricarbocyanine-labeled human serum albumin and transferrin.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Conformation and structure of polymeric contrast agents for medical imaging

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The role of molecular conformation on tumor uptake of polymeric contrast agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Biological evaluation of polyester dendrimer: poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Transport of molecules across tumor vasculature

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.200700159

1 reference

7 January 2021

Enzyme and Proton-Activated Prodrugs for a Selective Cancer Therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Synthesis and Degradation of pH-Sensitive Linear Poly(amidoamine)s

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Polyketal nanoparticles: a new pH-sensitive biodegradable drug delivery vehicle

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Polyacetal−Doxorubicin Conjugates Designed for pH-Dependent Degradation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Bioreductive and gene therapy approaches to hypoxic diseases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Quinone bioreductive prodrugs as delivery agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

5'-(2-Nitrophenylalkanoyl)-2'-deoxy-5-fluorouridines as potential prodrugs of FUDR for reductive activation.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Sigmatropic reactions of the aziridinyl semiquinone species. Why aziridinyl benzoquinones are metabolically more stable than aziridinyl indoloquinones

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Depurinating Acylfulvene−DNA Adducts: Characterizing Cellular Chemical Reactions of a Selective Antitumor Agent

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Immunotoxin treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Immunotoxins for targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The role of cellular proteases and their inhibitors in invasion and metastasis. Introductionary overview

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Tumor cell interactions with the extracellular matrix during invasion and metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Changing views of the role of matrix metalloproteinases in metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Recent advances in the synthesis, design and selection of cysteine protease inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Lysosomal cysteine proteases (cathepsins): promising drug targets.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Aspartic peptidase inhibitors: implications in drug development

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The design of inhibitors for medicinally relevant metalloproteins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Intensely cytotoxic anthracycline prodrugs: glucuronides

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

A novel connector linkage applicable in prodrug design

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Self-immolative dendrimers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

“Cascade‐Release Dendrimers” Liberate All End Groups upon a Single Triggering Event in the Dendritic Core

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Dendrimer disassembly by benzyl ether depolymerization

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Dendrimer disassembly as a new paradigm for the application of dendritic structures

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Single-triggered trimeric prodrugs.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Receiver-amplifier, self-immolative dendritic device.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Self-immolative dendrimer biodegradability by multi-enzymatic triggering

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Enzymatic activation of second-generation dendritic prodrugs: Conjugation of self-immolative dendrimers with poly(ethylene glycol) via click chemistry

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Mylotarg: antibody-targeted chemotherapy comes of age.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The enediyne antibiotics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Cleavage behavior of calicheamicin gamma 1 and calicheamicin T

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Antimitotic Activity of the Potent Tumor Inhibitor Maytansine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Binding of maytansine to rat brain tubulin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.200700159

1 reference

7 January 2021

Tumor inhibitors. 96. Novel maytansinoids. Structural interrelations and requirements for antileukemic activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Chemical modification of ansamitocins. II. Synthesis of 3-epimaytansionoids via 3-maytansinones

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Eradication of large colon tumor xenografts by targeted delivery of maytansinoids

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Folate-maytansinoids: target-selective drugs of low molecular weight.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Recent developments in the maytansinoid antitumor agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Interaction of dolastatin 10 with bovine brain tubulin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

High-molecular weight HPMA copolymer-adriamycin conjugates.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Synthesis of starlike N-(2-hydroxypropyl)methacrylamide copolymers: potential drug carriers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Polymeric anticancer drugs with pH-controlled activation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Degradation of camptothecin-20(S)-glycinate ester prodrug under physiological conditions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Designing dendrimers for biological applications

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.200700159

1 reference

7 January 2021

In vitro and in vivo evaluation of hydrophilic dendronized linear polymers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Designing macromolecules for therapeutic applications: polyester dendrimer-poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Synthesis and self-assembly of supramolecular dendritic "Bow-Ties": effect of peripheral functionality on association constants

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Targeting of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate to the hepatocyte galactose-receptor in mice: visualisation and quantification by gamma scintigraphy as a basis for clinical targeting studies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Doxorubicin coupled to lactosaminated human albumin remains confined within mouse liver cells after the intracellular release from the carrier.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Anticancer carrier-linked prodrugs in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Monoclonal antibodies for the treatment of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Activation and cytotoxicity of 2-alpha-aminoacyl prodrugs of methotrexate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT)

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Bioactivation of carbamate-based 20(S)-camptothecin prodrugs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Cathepsin B and glioma invasion

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Influence of a peptide linker on biodistribution and metabolism of antibody-conjugated benzyl-EDTA. Comparison of enzymatic digestion in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

An improved cathepsin-D substrate and assay procedure

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: Correlation with metastatic behavior in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The plasminogen activation system in tumor growth, invasion, and metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Membrane proteases in focus

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA)

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Substrate specificity of tissue type plasminogen activator. Characterization of the fibrin independent specificity of t-PA for plasminogen

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

A history of prostate cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The chymotrypsin-like activity of human prostate-specific antigen, gamma-seminoprotein

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Expression and function of beta-glucuronidase in pancreatic cancer: potential role in drug targeting

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The role of beta-glucuronidase in drug disposition and drug targeting in humans

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Glucuronides in anti-cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Beta-glucuronidase-mediated drug release

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Identification of the cytosolic carboxylesterase catalyzing the 5'-deoxy-5-fluorocytidine formation from capecitabine in human liver

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

A new linker for glucuronylated anticancer prodrugs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Drug delivery systems based on trimethyl lock lactonization: poly(ethylene glycol) prodrugs of amino-containing compounds

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Coumarin-based prodrugs. Part 3: Structural effects on the release kinetics of esterase-sensitive prodrugs of amines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Chemical feasibility studies of a potential coumarin-based prodrug system

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Imaging of angiogenesis: from microscope to clinic

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700159

7 January 2021

Identifiers

DOI

10.1002/CMDC.200700159

1 reference

17 August 2017

1 reference